



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

TMT OR ECHO

TMT OR ECHO

GOOD LV SYSTOLIC FUNCTION AT REST

Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 1 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG WITHIN NORMAL LIMITS

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS NO FOCAL PARENCHYMAL LESION NOTED

MEDICAL HISTORY

RELEVANT PRESENT HISTORY	ACIDITY ON AND OFF SMALL JOINT PAIN
RELEVANT PAST HISTORY	MALARIA AND TYPHOID IN CHILDHOOD
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT
RELEVANT FAMILY HISTORY	HYPERTENSION, HEART DISEASE
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS	1.58	mts
WEIGHT IN KGS.	66.3	Kgs
BMI	27	kg/sqmts

BMI & Weight Status as follows
 Below 18.5: Underweight
 18.5 - 24.9: Normal
 25.0 - 29.9: Overweight
 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER

Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH
Consultant Physician



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : **0002VL018518**
 PATIENT ID : SUHRF0109672A
 CLIENT PATIENT ID:
 ABHA NO :


AGE/SEX : 55 Years Female
 DRAWN : 10/12/2022 08:07:22
 RECEIVED : 10/12/2022 08:08:47
 REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

THYROID GLAND	NOT ENLARGED			
CAROTID PULSATION	NORMAL			
TEMPERATURE	NORMAL			
PULSE	60/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT			
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
BP	140/70 MM HG (SUPINE)			mm/Hg
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	S1, S2 HEARD NORMALLY			
MURMURS	ABSENT			
RESPIRATORY SYSTEM				
SIZE AND SHAPE OF CHEST	NORMAL			
MOVEMENTS OF CHEST	SYMMETRICAL			
BREATH SOUNDS INTENSITY	NORMAL			
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)			
ADDED SOUNDS	ABSENT			
PER ABDOMEN				
APPEARANCE	NORMAL			
VENOUS PROMINENCE	ABSENT			
LIVER	NOT PALPABLE			
SPLEEN	NOT PALPABLE			
HERNIA	ABSENT			
CENTRAL NERVOUS SYSTEM				
HIGHER FUNCTIONS	NORMAL			
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
MOTOR SYSTEM	NORMAL			
REFLEXES	NORMAL			
MUSCULOSKELETAL SYSTEM				



Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist



Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 3 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : **0002VL018518**
 PATIENT ID : SUHRF0109672A
 CLIENT PATIENT ID:
 ABHA NO :


AGE/SEX : 55 Years Female
 DRAWN : 10/12/2022 08:07:22
 RECEIVED : 10/12/2022 08:08:47
 REPORTED : 12/12/2022 18:06:58

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

SPINE	NORMAL
JOINTS	NORMAL
BASIC EYE EXAMINATION	
CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (6/9)
DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (6/9)
NEAR VISION RIGHT EYE WITH GLASSES	WITHIN NORMAL LIMIT (N6)
NEAR VISION LEFT EYE WITH GLASSES	WITHIN NORMAL LIMIT (N6)
COLOUR VISION	NORMAL (17/17)
BASIC ENT EXAMINATION	
EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	NORMAL
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED
BASIC DENTAL EXAMINATION	
TEETH	NORMAL
GUMS	HEALTHY
SUMMARY	
RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT



Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist



Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 4 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

RELEVANT LAB INVESTIGATIONS

RAISED HBA1C (5.8)
 RAISED EAG (119.8)
 RAISED FBS (114)
 RAISED CHOLESTEROL (256)
 RAISED TRIGLYCERIDES (173)
 RAISED LDL (173)
 RAISED NON HDL (208)
 RAISED GGT (45)
 RAISED POTASSIUM (5.30)
 RAISED CHLORIDE (107)

RELEVANT NON PATHOLOGY DIAGNOSTICS


USG-GRADE I FATTY LIVER

REMARKS / RECOMMENDATIONS

RAISED FBS,RAISED HBA1C,RAISED GGT
 REDUCE SATURATED FATS IN DIET
 FOLLOW UP WITH PHYSICIAN FOR RAISED LIPID PROFILE



Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist



Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 5 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	<u>Final</u>	Results	Units
--------------------	--------------	---------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN


- GRADE I FATTY LIVER.
- CALCIFIC INTRAMURAL /SUBSEROUS LEFT LATERAL UTERINE FIBROID (22 X 20 MM).

Interpretation(s)

MEDICAL HISTORY_***** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.



**Dr. Swati Karmarkar,
MD,DNB,DMRD
Consultant Radiologist**



**Dr. J N Shukla ,MBBS, AFIH
Consultant Physician**



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	12.1	12.0 - 15.0	g/dL
METHOD : PHOTOMETRIC MEASUREMENT			
RED BLOOD CELL (RBC) COUNT	4.23	3.8 - 4.8	mil/ μ L
METHOD : COULTER PRINCIPLE			
WHITE BLOOD CELL (WBC) COUNT	6.00	4.0 - 10.0	thou/ μ L
METHOD : COULTER PRINCIPLE			
PLATELET COUNT	172	150 - 410	thou/ μ L
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	36.7	36.0 - 46.0	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	86.8	83.0 - 101.0	fL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.5	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	32.9	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	13.9	11.6 - 14.0	%
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM			
MENTZER INDEX	20.5		
MEAN PLATELET VOLUME (MPV)	12.6 High	6.8 - 10.9	fL
METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	57	40 - 80	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
LYMPHOCYTES	32	20 - 40	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
MONOCYTES	6	2.0 - 10.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
EOSINOPHILS	4	1.0 - 6.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			

Dr. Sushant Chikane
Consultant Pathologist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
BASOPHILS		1	0 - 1	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT		3.42	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		1.92	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.36	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.24	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0.06	0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.8		
METHOD : CALCULATED				

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
 RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
 (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
 This ratio element is a calculated parameter and out of NABL scope.

Dr. Sushant Chikane
Consultant Pathologist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD

E.S.R	20	0 - 20	mm at 1 hr
-------	----	--------	------------

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Sushant Chikane
Consultant Pathologist

Page 9 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	O
METHOD : HAEMAGGLUTINATION (AUTOMATED)	
RH TYPE	POSITIVE
METHOD : HAEMAGGLUTINATION (AUTOMATED)	

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane
Consultant Pathologist

Page 10 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C **5.8 High** Non-diabetic Adult < 5.7 %
 Pre-diabetes 5.7 - 6.4
 Diabetes diagnosis: > or = 6.5
 Therapeutic goals: < 7.0
 Action suggested : > 8.0
 (ADA Guideline 2021)

METHOD : ION- EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) **119.8 High** < 116.0 mg/dL
 METHOD : CALCULATED PARAMETER

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) **114 High** Normal <100 mg/dL
 Impaired fasting glucose:100 to 125
 Diabetes mellitus: > = 126 (on more than 1 occassion)
 (ADA guidelines 2021)

METHOD : SPECTROPHOTOMETRY HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) **122** Normal <140 mg/dL
 Impaired glucose tolerance:140 to 199
 Diabetes mellitus : > = 200 (on more than 1 occassion)
 ADA guideline 2021

METHOD : SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL **256 High** Desirable : < 200 mg/dL
 Borderline : 200 - 239
 High : > / = 240

METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES **173 High** Normal: < 150 mg/dL
 Borderline high: 150 - 199
 High: 200 - 499
 Very High: >/= 500

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

S.S.Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
HDL CHOLESTEROL		48	At Risk: < 40 Desirable: > or = 60	mg/dL
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC				
CHOLESTEROL LDL		173 High	Optimal : < 100 Near optimal/above optimal : 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL
METHOD : CALCULATED PARAMETER				
NON HDL CHOLESTEROL		208 High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
METHOD : CALCULATED PARAMETER				
CHOL/HDL RATIO		5.3 High	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PARAMETER				
LDL/HDL RATIO		3.9 High	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0	
METHOD : CALCULATED PARAMETER				
VERY LOW DENSITY LIPOPROTEIN		35.0 High	< or = 30.0	mg/dL
METHOD : CALCULATED PARAMETER				

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3) HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5) Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals	Consider Drug Therapy
------------	-----------------	-----------------------

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : **0002VL018518**
 PATIENT ID : SUHRF0109672A
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 55 Years Female
 DRAWN : 10/12/2022 08:07:22
 RECEIVED : 10/12/2022 08:08:47
 REPORTED : 12/12/2022 18:06:58

Test Report Status **Final** Results Biological Reference Interval Units

	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal < OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.40	Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - DIAZO METHOD			
BILIRUBIN, DIRECT	0.18	0.0 - 0.2	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION			
BILIRUBIN, INDIRECT	0.22	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.2	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BIURET, REAGENT BLANK, SERUM BLANK			
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING			
GLOBULIN	2.7	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.7	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	25	Upto 32	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	30	Upto 33	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC			
ALKALINE PHOSPHATASE	100	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	45 High	< 40	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC			
LACTATE DEHYDROGENASE	156	< 223	U/L

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
 (Reg.no.MMC2012/06/1868)
 Junior Biochemist

Page 14 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 9 6 - 20 mg/dL

METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC

CREATININE, SERUM

CREATININE 0.67 0.60 - 1.10 mg/dL

METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARDIZED

BUN/CREAT RATIO

BUN/CREAT RATIO 13.43 8 - 15

METHOD : CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 5.6 2.4 - 5.7 mg/dL

METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.2 6.0 - 8.0 g/dL

METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK

ALBUMIN, SERUM

ALBUMIN 4.5 3.97 - 4.94 g/dL

METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING

GLOBULIN

GLOBULIN 2.7 2.0 - 3.5 g/dL

METHOD : CALCULATED PARAMETER

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM 142 136 - 145 mmol/L

METHOD : ISE INDIRECT

POTASSIUM, SERUM **5.30 High** 3.5 - 5.1 mmol/L

METHOD : ISE INDIRECT

CHLORIDE, SERUM **107 High** 98 - 106 mmol/L

METHOD : ISE INDIRECT

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
 - Diagnosing diabetes.
 - Identifying patients at increased risk for diabetes (prediabetes).
- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.
- eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
 - eAG gives an evaluation of blood glucose levels for the last couple of months.
 - eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

- Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
- Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- Interference of hemoglobinopathies in HbA1c estimation is seen in
 - Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
 (Reg.no.MMC2012/06/1868)
 Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c.HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonyleureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis,obstruction of bile ducts,cirrhosis.

ALP is a protein found in almost all body tissues.Tissues with higher amounts of ALP include the liver,bile ducts and bone.Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles.The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity.Serum GGT has been widely used as an index of liver dysfunction.Elevated serum GGT activity can be found in diseases of the liver,biliary system and pancreas.Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.Serum total protein,also known as total protein,is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom's disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is

S.S.Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease
 Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.
 ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MICRO BIOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

MICROSCOPIC EXAMINATION,STOOL

REMARK SAMPLE NOT RECEIVED

Dr. Ekta Patil,MD
(Reg.No. MMC2008/04/1142)
Senior Microbiologist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : **0002VL018518**
 PATIENT ID : SUHRF0109672A
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 55 Years Female
 DRAWN : 10/12/2022 08:07:22
 RECEIVED : 10/12/2022 08:08:47
 REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of anti-diarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects & reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS :

- Stool Culture**:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin**: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test (FOBT)**: This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay**: This test is strongly recommended in healthcare associated bloody or watery diarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL**: In patients of Diarrhoea, Dysentery, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.



Dr. Ekta Patil, MD
 (Reg.No. MMC2008/04/1142)
 Senior Microbiologist

Page 20 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

6. **Rota Virus Immunoassay:** This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomiting & abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Ekta Patil, MD
(Reg.No. MMC2008/04/1142)
Senior Microbiologist

Page 21 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW
 APPEARANCE SLIGHTLY HAZY

CHEMICAL EXAMINATION, URINE

PH	6.0	5.00 - 7.50
SPECIFIC GRAVITY	1.015	1.010 - 1.030
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NOT DETECTED	
NITRITE	DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	DETECTED (FEW)	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	2-3	0-5	/HPF
EPITHELIAL CELLS	5-7	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	DETECTED (+)	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
 (Reg.no.MMC2012/06/1868)
 Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
---------------------------	--------------	----------------	--------------------------------------	--------------

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED (2CV-28997)
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	THE SMEAR SHOWS MAINLY INTERMEDIATE SQUAMOUS CELLS, FEW SUPERFICIAL SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, OCCASIONAL CLUSTERS OF ENDOCERVICAL CELLS IN THE MODERATE BACKGROUND OF POLYMORPHS.
INTERPRETATION / RESULT	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY
-	REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION (INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION)
ENDOMETRIAL CELLS (IN A WOMAN >/= 45 YRS)	ABSENT

Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY,2014, 3rd Edition)
ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

- 1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.
- 2) No cytologic evidence of hpv infection in the smears studied.
- 3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.

Dr. Roopali Manudhane, MD
(Reg.No. MMC2013/10/3142)
Consultant Histopathologist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3	135.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester 105.0 - 230.0 2nd Trimester 129.0 - 262.0 3rd Trimester 135.0 - 262.0	ng/dL
----	-------	---	-------

METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

T4	7.69	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
----	------	---	-------

METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

TSH (ULTRASENSITIVE)	3.390	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL
----------------------	-------	---	--------

METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
---------------------------	--------------	----------------	--------------------------------------	--------------

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. Tietz Fundamentals of Clinical chemistry 2. Guidelines of the American Thyroid association during pregnancy and Postpartum, 2011.
NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4. TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402



MC-2010

PATIENT NAME : SUHRITA CHATTERJI 154306

REF. DOCTOR : SELF

ACCESSION NO : 0002VL018518	AGE/SEX : 55 Years Female
PATIENT ID : SUHRF0109672A	DRAWN : 10/12/2022 08:07:22
CLIENT PATIENT ID:	RECEIVED : 10/12/2022 08:08:47
ABHA NO :	REPORTED : 12/12/2022 18:06:58

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form
5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist

Page 27 Of 27



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011475402